EP4070728A1 — Displays for a medical device
Assigned to Abbott Diabetes Care Inc · Expires 2022-10-12 · 4y expired
What this patent protects
Embodiments described herein relate to a a glucose monitoring system, comprising a glucose sensor, wherein at least part of the glucose sensor is configured to be positioned in contact with interstitial fluid in a body of a user; a transmitter unit coupled to the glucose sensor a…
USPTO Abstract
Embodiments described herein relate to a a glucose monitoring system, comprising a glucose sensor, wherein at least part of the glucose sensor is configured to be positioned in contact with interstitial fluid in a body of a user; a transmitter unit coupled to the glucose sensor and configured to process glucose data indicative of a monitored glucose level from the glucose sensor; and a receiver unit comprising a processor and a user interface, wherein the receiver unit is configured to receive the processed glucose data from the transmitter unit; wherein the processor is configured to: detect an alert condition associated with the glucose monitoring system; suppress output of an alarm through the user interface for a predetermined wait period following detecting the alert condition, wherein the predetermined wait period is user-selectable; detect that the alert condition still exists after expiry of the predetermined wait period; and cause the user interface to output the alarm based on the detected alert condition still existing.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.